Fig. 4From: Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluationBase case Cost-effectiveness Acceptability Curves (CEAC); presenting the probability of cost-effectiveness of the two alternatives for a range of values of thresholds. Because the TIL is clearly dominant over ipilimumab, the lines do not cross each other.Back to article page